Cargando…
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
OBJECTIVE: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a nucleoside reverse transcriptase inhibitor (NRTI) backbone with respect to clinical, immunologic, and virologic outcomes. DESIGN: Prospective studies of human immunodeficiency virus (HIV)-infected ind...
Autores principales: | Cain, Lauren E., Caniglia, Ellen C., Phillips, Andrew, Olson, Ashley, Muga, Roberto, Pérez-Hoyos, Santiago, Abgrall, Sophie, Costagliola, Dominique, Rubio, Rafael, Jarrín, Inma, Bucher, Heiner, Fehr, Jan, van Sighem, Ard, Reiss, Peter, Dabis, François, Vandenhende, Marie-Anne, Logan, Roger, Robins, James, Sterne, Jonathan A. C., Justice, Amy, Tate, Janet, Touloumi, Giota, Paparizos, Vasilis, Esteve, Anna, Casabona, Jordi, Seng, Rémonie, Meyer, Laurence, Jose, Sophie, Sabin, Caroline, Hernán, Miguel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072966/ https://www.ncbi.nlm.nih.gov/pubmed/27741139 http://dx.doi.org/10.1097/MD.0000000000005133 |
Ejemplares similares
-
Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016) -
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016) -
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016) -
Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study
por: Nylén, Hanna, et al.
Publicado: (2016) -
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)